Dr. Avencia Sánchez-Mejías, CEO and Co-Founder of Integra Therapeutics, will speak at the first CRISPR Medicine Conference held April 23 to 25 in Copenhagen, Denmark.

The conference will bring together over 400 delegates from the European CRISPR medicine and genomic medicine community for two days of learning, networking and stimulating discussions.

The program includes talks by more than 70 renowned speakers from academia and industry, as well as several workshops focused on six main tracks that cover the most important topics in the therapeutic gene-editing field: Tools, Delivery, Safety, Functional Genomics, Standards and Regulations, Pre-clinical Research and Clinical Trials.

On Wednesday, April 24, at 4:45 pm CEST, Dr. Avencia Sánchez-Mejías will give a talk about Integra Therapeutics’ work titled FiCAT gene writing platform for advanced therapies in the Tools panel. This panel will be chaired by Dr. Anna Cereseto, Full Professor and Deputy director of the Department of Cellular, Computational and Integrative Biology (CIBIO) at the University of Trento, and Dr. Marcello Maresca, Senior Director of the Genome Engineering Department at AstraZeneca.

FiCAT is a latest generation tool for generating safer, more efficient advanced therapies that is in the preclinical phase and has shown very promising in vivo and ex vivo results.